All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

FDA elevates endovascular recall as Philips pulls Tack implant from the market

FDA elevates endovascular recall as Philips pulls Tack ...

Mar 4, 2025  0

Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

Sotio takes up option on ADCs, while Boehringer inks GP...

Mar 13, 2025  0

Evidation elevates COO to CEO, partners with AHA

Evidation elevates COO to CEO, partners with AHA

Mar 6, 2025  0